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Approaches to understanding susceptibility to nephropathy: such as polycystic kidney disease, because of the avail-
From genetics to genomics. The incidence of end-stage renal ability of families with multiple affected members. In
disease (ESRD) is increasing worldwide despite efforts to slow contrast, the complexity in the etiology of CRF and thethe progression of chronic renal failure (CRF) by controlling
variation in rate and number of individuals who progressblood pressure and hyperglycemia. Two available therapies for
to ESRD suggest that it is unlikely that the phenotypeESRD, dialysis and transplantation, are expensive and are at
best palliative. Recently, data from several laboratories have for most etiologies of CRF will be attributed to a single
demonstrated that ESRD is under substantial genetic control, gene. Because high-throughput technologies for genetic
and efforts to identify these genetic determinants are under- mapping are now accessible to many researchers, recruit-way. Identifying genes for ESRD pathogenesis has several
ment of sib pairs or families with nephropathy has beengoals. First, understanding the genetic basis of ESRD offers a
undertaken with the goal of identifying genes for themeans to clarify the mechanisms that result in kidney pathobiol-
ogy. Second, better and new treatments for prevention of pro- more common forms of CRF initiation or progression
gression of CRF to ESRD may be developed. Third, individuals by candidate gene and/or whole genome analyses. As an
at risk could be identified early in their course and targeted
alternative strategy to family collection for identifyingfor intensive therapy. Finally, the products of genes causing
nephropathy susceptibility genes, gene expression analy-disease become target molecules for gene therapy. In this arti-
cle, we discuss data from our laboratories, which employ two ses that use novel molecular techniques, such as expres-
different molecular genetic strategies for identifying ESRD sion microarrays or serial analysis of gene expression
pathogenesis genes. In contrast to traditional experimental de- (SAGE), have been proposed. These assays simultane-sign, both approaches are hypothesis generating, identifying
ously determine the expression patterns of multiple genescandidate molecules for further study, rather than hypothesis
in a specific tissue or cell type. The ultimate goal ofdriven and may provide novel insights into mechanisms of renal
disease progression. either approach is to identify molecules that will aid in
early prognosis or that can identify novel targets for ESRD
therapy.
End-stage renal disease (ESRD) is a serious health
problem in the United States and worldwide, with a 7%
METHODSannual increase in incidence over the last decade. The
major emphasis in kidney disease research has been in Genetic approach: family collection and analysis
determining hemodynamic alterations caused by reduc- Strategies for collection, phenotyping, and analysis of
tion in nephron number or mechanisms that result in families, in which nephropathy is clustered, have been
fibrosis, which subsequently leads to initiation and pro- published [1, 2]. Briefly, ESRD patients were screened
gression of chronic renal failure (CRF). However, molec- by questionnaire and medical record review (N  2900).
ular mechanisms of CRF remain incompletely under- To quantify the strength of familial clustering, we have
stood. Family- and population-based epidemiology, as determined two measures, sibling recurrence risk (SRR)
well as the cloning of several genes responsible for famil- and the SSR ratio (s), in our population of African
ial aggregation of renal disease, suggests that renal dis- American (AA) and Caucasian (CA) cases using inter-
ease initiation and progression is genetically determined. view-based family history data. SRR was computed by
Identifying genetic determinants is easier for single gene dividing the total number of affected sibs by the total
disorders that show Mendelian modes of inheritance, number of sibs. s was determined by dividing the SRR
by the point prevalence of ESRD from the USRDS data.
Key words: family studies, gene expression, SAGE, susceptibility, CRF. These variables were computed in a subset (N 1148) of
the ESRD patients completing a screening questionnaire 2002 by the International Society of Nephrology
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Fig. 1. A comparison of HCFA 2728 diagnostic categories demon-
strated significant differences between CAs and AAs. Hypertensive
nephrosclerosis was more common cause of ESRD among AAs,
whereas type 2 diabetes was equally frequent in the two ethnic groups.
Fig. 2. Data from the ESRD genetics project demonstrating that aggre-
gation of family history among AAs is greater than among CAs. We(available at http://kidney.metrohealth.org) [3]. Chi-square
observed that independent of race females demonstrated greater famil-
tests were used to determine significant ethnic differ- ial clustering.
ences between gender, age at first dialysis, and diagnosis
distribution in the entire population.
Genomic approach: generation of expression libraries in first-, second-, or third-degree relatives was reported
from ROP-Os/ and C57-OS/ mouse kidney by 33.9% (N  312) of ESRD index cases. Of these,
91% (24.9% of the total) reported that ESRD affectedTo identify genes that regulate renal disease progres-
at least one first-degree relative. Family members of AAsion, SAGE kidney mRNA profiles were contrasted
index cases showed a greater risk of developing ESRD,from sclerosis-prone ROP-Os/ and sclerosis-resistant
with 39% of AA compared with 29% of CA reportingC57BL/6-Os/ (C57-Os/) mice (abstract; El-Meanawy
a family history of ESRD in first, second-, or third-degreeet al, J Am Soc Nephrol 11:617A, 2000) [4, 5]. SAGE
relatives (Fig. 2). To quantify the strength of familialpermits comparative, quantitative analysis of gene-spe-
clustering, we have determined SRR and s in our popu-cific, 9 to 13 bp sequence tag libraries, and methods have
lation of AA and CA cases using interview-based familybeen published [6, 7]. P values were determined for the
history data. We observed that SRR was high in bothdifference in tag counts between the two libraries using
AAs and CA (0.062  0.011 vs. 0.056  0.011) but in athe winflat program [8], which assumes a Poisson distri-
range expected for a complex disease. In contrast, thebution for the number of observed tags.
s for ESRD was extremely high in AA (s  18.6) but
was even higher in CA (s  58.6) [3]. The increasedRESULTS prevalence of ESRD in AA suggests that ESRD suscep-
Family members of AA and CA ESRD index cases tibility alleles have obtained a high frequency in the AA
are at risk for developing ESRD population. Alternatively, the relatively greater s in AA
may be due to more nongenetic causes of ESRD oc-Patients from 13 dialysis units in the Greater Cleve-
curring in AA compared with CA.land Metropolitan area (Network 9) were approached
for the study (N 1148). Informed consent was obtained
Discovery of nephropathy pathogenesis genes usingfrom 952 index cases with ESRD. The remaining patients
expression libraries in experimental models of CRFeither declined or were unable to participate because of
reduced mental capacity or inability to communicate. The ROP-Os/mouse demonstrates progressive renal
failure from FSGS that cosegregates with oligosyndac-We restricted our analyses to CA (N  300) and AA
(N  621), the predominant ethnic populations in our taly [9]. The Os mutation, originally generated by ran-
dom radiation mutagenesis, has been mapped to mousesample (Fig. 1). A comparison of Health Care Financing
Corporation (HCFA) 2728 diagnostic categories showed chromosome 8 [10], but the specific gene has not been
isolated. Development of glomerulosclerosis is depen-significant differences between CA and AA (2 78.097,
P  0.0001). Hypertensive nephrosclerosis was more dent on the genetic background of the animal [11].
C57BL6 mice are resistant to development of glomerulo-prevalent among the AA index cases, but in this sample,
type 2 diabetes as a cause of ESRD was equally frequent sclerosis despite carrying the Os mutation, whereas ROP
mice carrying the same mutation develop glomeruloscle-in the two ethnic groups (Fig. 1). Family history of ESRD
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Fig. 3. Twenty-five SAGE tags demonstrated
differential expression patterns between the
ROP-Os/ and C57-Os/ renal libraries. Each
bar on the x axis corresponds to a tag, whereas
the units on the y axis represent that tag fre-
quency. Twelve tags are overexpressed, and
thirteen tags are underexpressed in the ROP-
Os/ library.
rosis and die of renal failure. To identify important CRF- pletely understood. Interindividual variability in the re-
nal responses to stochastic events, for example, highrelated genes, we have used SAGE, which is an empiric
blood pressure or hyperglycemia, has suggested thatapproach that makes no a priori assumptions about dis-
genes may regulate mechanisms of CRF. We have ap-ease pathogenesis, rather than testing the roles of a finite
plied two types of molecular genetic strategies to testnumber of predetermined molecular pathways that may
this hypothesis. First, we designed a study that will usehave a limited application to renal failure. Renal function
genetic or positional cloning approaches to identify dis-and histology were assessed in ROP-Os/ and C57-Os/
ease susceptibility genes. Positional cloning methods cor-mice from 6 to 16 weeks of age to establish the earliest
relate disease or trait status in families or in cases andtime point of renal disease onset and maximize isolation
controls with anonymous genetic markers without as-of pathogenesis genes. Glomerular sclerosis scores were
suming any knowledge about the function or location ofdetermined by computer-aided quantitative morphome-
the putative susceptibility gene. Second, we used noveltry, and urine albumin/creatinine demonstrated that ne-
gene expression technology (SAGE) to conduct analysesphropathy began as early as six weeks in ROP-Os/
of gene function on a global scale (genomics). Simultane-mice but was not manifest in C57-Os/ mice (data not
ous examination of gene expression profiles for a largeshown). Thus far, 17,042 and 21,419 tags have been iden-
number of genes from diseased and normal kidneystified in six-week ROP-Os/ and C57-Os/ kidney ex-
should yield differentially expressed genes that play apression libraries, respectively, and compared as described
role in the disease process. Using a genetic approach, wein the Methods section. Only 25 tags are expressed at
demonstrate a substantial genetic risk for nephropathy insignificantly different levels between libraries (Fig. 3);
first-degree relatives of both CA and AA ESRD pro-12 are overexpressed and 13 are underexpressed in the
bands. Using a genomic approach, we have identifiedROP-Os/ library. For example, enhanced expression
candidate nephropathy susceptibility genes in an animal(2- to 3-fold) of glutathione peroxidase in ROP-Os/
model of focal segmental glomerulosclerosis (FSGS).mouse kidney suggests a compensatory response to in-
There is substantial evidence that ESRD aggregatescreased oxidant stress, which may be an early mechanism
in families [12–14]. The increased aggregation of ESRDof sclerosis pathogenesis in this model. These data sug-
in families cannot be completely accounted for by greatergest that comprehensive characterization and compari-
prevalence of co-morbid phenotypes, such as diabetesson of gene expression patterns in normal and diseased
mellitus, hypertension, hypertension severity, inadequatekidneys will provide novel targets for therapeutic inter-
antihypertensive therapy, or socioeconomic status [15–19].vention by identifying candidate pathways, which regu-
We conducted a cross-sectional study of familial aggrega-late nephropathy pathogenesis.
tion of ESRD in a dialysis population from Cleveland,
Ohio. Using HCFA 2728 diagnosis, we observed that
DISCUSSION hypertensive nephrosclerosis was more frequent in AA,
Although mechanisms of renal disease progression whereas type 2 diabetes was equally frequent in both
ethnic groups (Fig. 1). Relative to males, we observedhave been clarified, ESRD pathogenesis remains incom-
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Table 1. A synopsis of renal gene expression analyses collated from the literature
Method Experiment Organism Reference
Subtractive hybridization Nephrogenesis Mouse [48]
Subtractive hybridization Androgen regulation Mouse [49, 50]
Subtractive hybridization Renal cell carcinoma Human [51]
Subtractive hybridization Diabetic nephropathy Human [52, 53]
Subtractive hybridization Wilms’ tumor Human [54]
Differential display Nephrolithiasis Mouse [55]
Differential display Nephrogenesis Rat explants, mouse [56–58]
Differential display Aging Mouse [59]
Differential display Nephrotic syndrome Human [60, 61]
Differential display Diabetic nephropathy Cultured human cells [62]
Differential display Diabetic nephropathy Rat [63]
SAGE Normal kidney and nephron tubule segments Mouse [46]
SAGE Normal kidney Mouse [6]
Microarray Renal cell carcinoma Human [64, 65]
Microarray Nephrogenesis Cultured cells [47, 66]
Microarray Renal cortex Human [67]
Microarray Renal inner medulla Mouse [68]
that both AA and CA females report a 1.5-fold increased causes of ESRD, such as diabetic nephropathy and hy-
pertensive nephrosclerosis, have yet to be characterized.risk of reporting an additional family member with
ESRD. Surprisingly, when the risk to siblings of AA and The primary disadvantage in the case of diabetic ne-
phropathy has been the lack of availability of large fami-CA index cases was quantified, s was high in AA but
even higher in CA. Although data from our and other lies and complex (nonmendelian) modes of inheritance.
Thus, most researchers have resorted to collecting af-laboratories indicate that nephropathy demonstrates
strong familial aggregation, segregation and co-mingling fected or discordant sib pairs to map genes for this dis-
ease. A collection of sib pairs for mapping complex dis-analyses are the only established methods for determin-
ing whether a phenotype (clinical measure or trait) fits eases has been fostered by development of analytic
methods that do not require assumptions about specifica particular genetic model. Two recent segregation anal-
yses have suggested a major locus controls albumin ex- genetic models (model-free linkage analysis) [reviewed
in 33, 34]. Using the affected sib pair method, a genome-cretion rate [20, 21]. In one study, proteinuria was ana-
lyzed as a continuous variable, with the conclusion that wide scan in Pima with diabetic nephropathy yielded
three potential loci (two on chromosome 7, one on chro-proteinuria was influenced by multiple genes with vari-
able effects [20]. The report by Imperatore et al in dia- mosome 20) [35]. Similarly, using type 1 diabetic sib pairs
discordant for nephropathy, Moczulski et al identified abetic Pima families considered proteinuria as a discrete
variable and determined that it was influenced by a major 20 cM region on chromosome 3q near the type I angio-
tensin II receptor as a major locus for nephropathy sus-gene effect [21]. Two studies of type 2 diabetic nephropa-
thy partitioned the genetic and environmental influences ceptibility [36], but the specific gene(s) within this locus
that regulates nephropathy has not been identified. Ourin albumin excretion rate and estimated heritability (h2),
a measure of genetic predisposition [22, 23]. Both studies group has focused on mapping genes for the diabetic
nephropathy phenotype [1–3] and is collecting CA andestimated the heritability for urinary albumin excretion
to be approximately 30%. The estimated heritability for AA sib pairs with and without type 2 diabetic nephropa-
thy. Additionally, we are members of the Family Investi-urine albumin excretion was statistically significant, even
after adjusting for potential confounding covariables, gation of Diabetes and Nephropathy consortium, which
is a joint mapping effort with the National Institute ofsuch as age, gender, body weight, diabetes duration, and
environment, suggesting a major genetic effect for pro- Digestive, Diabetes and Kidney Diseases and seven
other member institutions to map genes for diabetic ne-teinuria [22]. Finally, a biopsy study of resemblance of
type 1 diabetic sibs demonstrated a high degree of corre- phropathy (http://darwin.cwru.edu/research/find/).
Traditional genetic analyses of humans and model or-lation between severity and patterns of glomerular le-
sions despite lack of concurrence in the course of glyce- ganisms attempt to identify loci that cosegregate with a
specific disease phenotype [36]. However these tech-mia between sibs [24]. Thus, there is significant evidence
from a number of studies that ESRD pathogenesis is niques, although valuable, focus on a limited number
of genes at a time and do not examine mitochondrialpartly regulated by genes.
Mutations in specific genes have been identified in genomes. Recently, alternative methods have been de-
veloped to determine the mechanism by which genes actfamilies with Mendelian inheritance patterns of renal
disease [25–32]. In comparison, genes for other main in concert. These techniques include differential display,
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subtraction hybridization, gene expression analysis using elements) or protein (for example, kinase domain) mo-
tifs.microarrays, and SAGE [reviewed in 37–39]. Although
these techniques represent technological advances, with In the future, we anticipate that results from genetic
and genomic technologies will be used in tandem tothe exception of SAGE, all suffer from lack of quantifi-
cation. Differential display and subtraction hybridization comprehend the pathobiology of complex diseases such
as nephropathy. For example, once a candidate gene isare well-established techniques, whereas expression mi-
croarrays and SAGE are recent discoveries. The advan- identified through genetic analyses, the interaction of this
gene with others that causes disease can be clarified usingtage of the latter two techniques is that they are high-
throughput methods. Each of these techniques permits expression profiling. In conclusion, both techniques have
weaknesses that can be overcome by pairing the technol-comparison of expression profiles between multiple sam-
ples. Differential display, subtractive hybridization, and ogies in future research.
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